Keystone Symposia

This meeting took place in 2016

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Drug Discovery for Parasitic Diseases (A5)

Organizer(s) Leann M. Tilley, Philip J. Rosenthal and Kelly Chibale
January 24—28, 2016
Granlibakken Tahoe • Tahoe City, CA USA
Discounted Abstract Deadline: Sep 28, 2015
Abstract Deadline: Oct 28, 2015
Scholarship Deadline: Sep 28, 2015
Discounted Registration Deadline: Nov 23, 2015

Supported by the Directors' Fund

Summary of Meeting:
Parasitic organisms, including protozoa and helminths, are among the most significant human pathogens, causing billions of infections and millions of deaths each year. For many parasitic diseases, available therapies are unsatisfactory and increasingly threatened by drug resistance. New therapies, ideally directed against novel targets, are urgently needed. Recent advances in anti-parasitic drug discovery have come from three different approaches – target-based methods that build on improved understanding of parasite biology; phenotypic high-throughput screens that are benefitting from improved technology; and repositioning and repurposing drugs developed for other indications. These different approaches all benefit from the integration of medicinal chemistry with parasitology and pharmacotherapy programs. This conference will showcase cutting-edge anti-parasitic drug discovery programs that illustrate the path from parasite biology to lead identification and from optimization to candidate selection. It will emphasize the need for coordinated integration of programs in medicinal chemistry, parasite biology, pharmacokinetics and safety assessment. It will feature emerging technologies such as chemical biology, chemoproteomics, chemical informatics, genomics, transcriptomics and metabolomics that are facilitating drug discovery. It will also discuss the current status of anti-parasitic drug resistance and advances in our understanding of mechanisms of resistance. The conference should be of interest to medicinal chemists, parasitologists, experts in drug discovery and development, pharmacologists and clinicians targeting the protozoa and helminths that cause serious human disease, including malaria, African and American trypanosomiasis, leishmaniasis, schistosomiasis and multiple other parasitic infections.

View Meeting Program


Keystone Symposia Future of Science Fund Scholarship Recipients

Marvin Duvalsaint
University of South Florida, USA

Sarah Preston
University of Melbourne, Australia

National Institute of Allergy and Infectious Diseases (NIAID) Scholarship Recipients

Vitul Jain
International Centre for Genetic Engineering and Biotechnology, ICGEB, India

Caroline Ng
University of Nebraska Medical Center, USA

Taher Uddin
University of Melbourne, Australia